What does matrix metalloproteinase-1 expression in patients with breast cancer really tell us?

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107. Sorlie T: Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 2004, 40: 2667-2675. 10.1016/j.ejca.2004.08.021. Sorlie T: Introducing molecular subtyping of breast cancer into the clinic?. J Clin Oncol. 2009, 27: 1153-1154. 10.1200/JCO.2008.20.6276. Sorlie T: Molecular classification of breast tumors: toward improved diagnostics and treatments. Methods Mol Biol. 2007, 360: 91-114. Borgan E, Sitter B, Lingjaerde OC, Johnsen H, Lundgren S, Bathen TF, Sorlie T, Borresen-Dale AL, Gribbestad IS: Merging transcriptomics and metabolomics--advances in breast cancer profiling. BMC Cancer. 2010, 10: 628-10.1186/1471-2407-10-628. Zhao X, Rodland EA, Sorlie T, Naume B, Langerod A, Frigessi A, Kristensen VN, Borresen-Dale AL, Lingjaerde OC: Combining gene signatures improves prediction of breast cancer survival. PLoS One. 2011, 6: e17845-10.1371/journal.pone.0017845. Mannello F: Natural bio-drugs as matrix metalloproteinase inhibitors: new perspectives on the horizon?. Recent Pat Anticancer Drug Discov. 2006, 1: 91-103. 10.2174/157489206775246421. Mannello F, Luchetti F, Falcieri E, Papa S: Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis. 2005, 10: 19-24. 10.1007/s10495-005-6058-7. Mannello F, Gazzanelli G: Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications. Apoptosis. 2001, 6: 479-482. 10.1023/A:1012493808790. Tonti GA, Mannello F, Cacci E, Biagioni S: Neural stem cells at the crossroads: MMPs may tell the way. Int J Dev Biol. 2009, 53: 1-17. 10.1387/ijdb.082573gt. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO: Regulation of matrix metalloproteinase activity in health and disease. FEBS J. 2011, 278: 28-45. 10.1111/j.1742-4658.2010.07920.x. Mannello F, Tonti G, Papa S: Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr Cancer Drug Targets. 2005, 5: 285-298. 10.2174/1568009054064615. Kessenbrock K, Plaks V, Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010, 141: 52-67. 10.1016/j.cell.2010.03.015. Gialeli C, Theocharis AD, Karamanos NK: Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011, 278: 16-27. 10.1111/j.1742-4658.2010.07919.x. Cauwe B, Opdenakker G: Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit Rev Biochem Mol Biol. 2010, 45: 351-423. 10.3109/10409238.2010.501783. Yan C, Boyd DD: Regulation of matrix metalloproteinase gene expression. J Cell Physiol. 2007, 211: 19-26. 10.1002/jcp.20948. Roy R, Yang J, Moses MA: Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 2009, 27: 5287-5297. 10.1200/JCO.2009.23.5556. Delassus GS, Cho H, Hoang S, Eliceiri GL: Many new down- and up-regulatory signaling pathways, from known cancer progression suppressors to matrix metalloproteinases, differ widely in cells of various cancers. J Cell Physiol. 2010, 224: 549-558. 10.1002/jcp.22157. Gutierrez-Fernandez A, Fueyo A, Folgueras AR, Garabaya C, Pennington CJ, Pilgrim S, Edwards DR, Holliday DL, Jones JL, Span PN, Sweep FC, Puente XS, López-Otín C: Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Res. 2008, 68: 2755-2763. 10.1158/0008-5472.CAN-07-5154. Lopez-Otin C, Palavalli LH, Samuels Y: Protective roles of matrix metalloproteinases: from mouse models to human cancer. Cell Cycle. 2009, 8: 3657-3662. 10.4161/cc.8.22.9956. McGowan PM, Duffy MJ: Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol. 2008, 19: 1566-1572. 10.1093/annonc/mdn180. Eltarhouny SA, Elsawy WH, Radpour R, Hahn S, Holzgreve W, Zhong XY: Genes controlling spread of breast cancer to lung "gang of 4". Exp Oncol. 2008, 30: 91-95. Eck SM, Blackburn JS, Schmucker AC, Burrage PS, Brinckerhoff CE: Matrix metalloproteinase and G protein coupled receptors: co-conspirators in the pathogenesis of autoimmune disease and cancer. J Autoimmun. 2009, 33: 214-221. 10.1016/j.jaut.2009.09.011. Baker AH, Edwards DR, Murphy G: Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci. 2002, 115: 3719-3727. 10.1242/jcs.00063. Kohrmann A, Kammerer U, Kapp M, Dietl J, Anacker J: Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer. 2009, 9: 188-10.1186/1471-2407-9-188. Boström P, Soderstrom M, Vahlberg T, Soderstrom KO, Roberts PJ, Carpen O, Hirsimaki P: MMP-1 expression has an independent prognostic value in breast cancer. BMC Cancer. 2011. Orimo A, Weinberg RA: Heterogeneity of stromal fibroblasts in tumors. Cancer Biol Ther. 2007, 6: 618-619. Hasebe Y, Egawa K, Shibanuma M, Nose K: Induction of matrix metalloproteinase gene expression in an endothelial cell line by direct interaction with malignant cells. Cancer Sci. 2007, 98: 58-67. 10.1111/j.1349-7006.2006.00344.x. Gao MQ, Kim BG, Kang S, Choi YP, Park H, Kang KS, Cho NH: Stromal fibroblasts from the interface zone of human breast carcinomas induce an epithelial-mesenchymal transition-like state in breast cancer cells in vitro. J Cell Sci. 2010, 123: 3507-3514. 10.1242/jcs.072900. Hasebe T, Iwasaki M, kashi-Tanaka S, Hojo T, Shibata T, Sasajima Y, Kinoshita T, Tsuda H: Atypical tumor-stromal fibroblasts in invasive ductal carcinoma of the breast. Am J Surg Pathol. 2011, 35: 325-336. Orimo A, Weinberg RA: Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle. 2006, 5: 1597-1601. 10.4161/cc.5.15.3112. Eck SM, Cote AL, Winkelman WD, Brinckerhoff CE: CXCR4 and matrix metalloproteinase-1 are elevated in breast carcinoma-associated fibroblasts and in normal mammary fibroblasts exposed to factors secreted by breast cancer cells. Mol Cancer Res. 2009, 7: 1033-1044. 10.1158/1541-7786.MCR-09-0015. Park YH, Jung HH, Ahn JS, Im YH: Ets-1 upregulates HER2-induced MMP-1 expression in breast cancer cells. Biochem Biophys Res Commun. 2008, 377: 389-394. 10.1016/j.bbrc.2008.09.135. Decock J, Hendrickx W, Vanleeuw U, V Van B, Van HS, Christiaens MR, Ye S, Paridaens R: Plasma MMP1 and MMP8 expression in breast cancer: protective role of MMP8 against lymph node metastasis. BMC Cancer. 2008, 8: 77-10.1186/1471-2407-8-77. Eck SM, Hoopes PJ, Petrella BL, Coon CI, Brinckerhoff CE: Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model. Breast Cancer Res Treat. 2009, 116: 79-90. 10.1007/s10549-008-0085-3. Eguchi T, Kubota S, Kawata K, Mukudai Y, Uehara J, Ohgawara T, Ibaragi S, Sasaki A, Kuboki T, Takigawa M: Novel transcription-factor-like function of human matrix metalloproteinase 3 regulating the CTGF/CCN2 gene. Mol Cell Biol. 2008, 28: 2391-2413. 10.1128/MCB.01288-07. Aldonyte R, Brantly M, Block E, Patel J, Zhang J: Nuclear localization of active matrix metalloproteinase-2 in cigarette smoke-exposed apoptotic endothelial cells. Exp Lung Res. 2009, 35: 59-75. 10.1080/01902140802406059. Polyak K, Kalluri R: The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb Perspect Biol. 2010, 2: a003244-10.1101/cshperspect.a003244. Yan C, Boyd DD: Regulation of matrix metalloproteinase gene expression. J Cell Physiol. 2007, 211: 19-26. 10.1002/jcp.20948. DeCosse JJ, Gossens CL, Kuzma JF, Unsworth BR: Breast cancer: induction of differentiation by embryonic tissue. Science. 1973, 181: 1057-1058. 10.1126/science.181.4104.1057. Wallace JA, Li F, Leone G, Ostrowski MC: Pten in the breast tumor microenvironment: modeling tumor-stroma coevolution. Cancer Res. 2011, 71: 1203-1207. 10.1158/0008-5472.CAN-10-3263. Cichon MA, Degnim AC, Visscher DW, Radisky DC: Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer. J Mammary Gland Biol Neoplasia. 2010, 15: 389-397. 10.1007/s10911-010-9195-8. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR, Polyak K: Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004, 6: 17-32. 10.1016/j.ccr.2004.06.010. Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC: Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 2009, 11: R7-10.1186/bcr2222. Brinckerhoff CE, Rutter JL, Benbow U: Interstitial collagenases as markers of tumor progression. Clin Cancer Res. 2000, 6: 4823-4830. Polyak K: Molecular markers for the diagnosis and management of ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010, 2010: 210-213. 10.1093/jncimonographs/lgq019. Bissell MJ, Radisky D: Putting tumours in context. Nat Rev Cancer. 2001, 1: 46-54. 10.1038/35094059. Stallings-Mann M, Radisky D: Matrix metalloproteinase-induced malignancy in mammary epithelial cells. Cells Tissues Organs. 2007, 185: 104-110. 10.1159/000101310. Radisky DC, Bissell MJ: Matrix metalloproteinase-induced genomic instability. Curr Opin Genet Dev. 2006, 16: 45-50. 10.1016/j.gde.2005.12.011. Bissell MJ, Kenny PA, Radisky DC: Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp Quant Biol. 2005, 70: 343-356. 10.1101/sqb.2005.70.013. Cheng S, Tada M, Hida Y, Asano T, Kuramae T, Takemoto N, Hamada J, Miyamoto M, Hirano S, Kondo S, Moriuchi T: High MMP-1 mRNA expression is a risk factor for disease-free and overall survivals in patients with invasive breast carcinoma. J Surg Res. 2008, 146: 104-109. 10.1016/j.jss.2007.05.032. Pearce EG, Laxton RC, Pereira AC, Ye S: Haplotype effects on matrix metalloproteinase-1 gene promoter activity in cancer cells. Mol Cancer Res. 2007, 5: 221-227. 10.1158/1541-7786.MCR-06-0139. Przybylowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J, Kolacinska A, Morawiec Z, Drzewoski J, Blasiak J: Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat. 2006, 95: 65-72. 10.1007/s10549-005-9042-6. Przybylowska K, Zielinska J, Zadrozny M, Krawczyk T, Kulig A, Wozniak P, Rykala J, Kolacinska A, Morawiec Z, Drzewoski J, Blasiak J: An association between the matrix metalloproteinase 1 promoter gene polymorphism and lymphnode metastasis in breast cancer. J Exp Clin Cancer Res. 2004, 23: 121-125. Mellick AS, Blackmore D, Weinstein SR, Griffiths LR: An assessment of MMP and TIMP gene expression in cell lines and stroma - tumour differences in microdissected breast cancer biopsies. Tumour Biol. 2003, 24: 258-270. 10.1159/000076140. Offit K, Robson ME: New pharmacogenomic paradigm in breast cancer treatment. J Clin Oncol. 2010, 28: 4665-4666. 10.1200/JCO.2010.31.2926. Chen ST, Pan TL, Juan HF, Chen TY, Lin YS, Huang CM: Breast tumor microenvironment: proteomics highlights the treatments targeting secretome. J Proteome Res. 2008, 7: 1379-1387. 10.1021/pr700745n. Kenny PA, Bissell MJ: Tumor reversion: correction of malignant behavior by microenvironmental cues. Int J Cancer. 2003, 107: 688-695. 10.1002/ijc.11491. Kenny PA, Lee GY, Bissell MJ: Targeting the tumor microenvironment. Front Biosci. 2007, 12: 3468-3474. 10.2741/2327. Kenny PA, Nelson CM, Bissell MJ: The Ecology of Tumors: By perturbing the microenvironment, wounds and infection may be key to tumor development. Scientist. 2006, 20: 30. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1741-7015/9/95/prepub